arrow
C

Claudio Anasetti

Moffitt Cancer Center
H指数:107
被引数:4.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia

肥胖及基于体重的化疗剂量调整对急性髓系白血病异基因造血细胞移植结局的影响

2025-10-200
PRE
Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide

Letermovir可降低接受移植后环磷酰胺治疗的HLA匹配和错配异基因造血细胞移植患者中的巨细胞病毒水平。

2025-07-050
PRE
Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes

美法仑剂量联合氟达拉滨影响急性髓系白血病和骨髓增生异常综合征异基因移植后胃肠道毒性和移植物抗宿主病

2024-11-010
PRE
Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide
2024-10-011
PRE
Mismatched donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations
2024-03-280
OAAI
Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide
2024-02-015
PRE
A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial
2023-06-014
OAAI
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial

使用移植后环磷酰胺的不匹配的无关骨髓供体移植接受者的三年结果: 来自国家骨髓供体计划赞助的前瞻性临床试验的随访

2023-03-0127
OAAI
Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo-inactivation and ILC2-mediated tissue repair
2022-03-013
OAAI
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease
2022-01-106
OAAI
Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation

与同种异体移植中常规GVHD预防相比,环磷酰胺移植后感染增加,CD4 T细胞延迟,但b细胞免疫重建更快

2021-11-0135
OAAI
ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

ELN 2017遗传风险分层预测接受异基因造血干细胞移植的急性髓系白血病患者的生存

2021-03-0113
OAAI
A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation
2021-02-2628
OA
Metabolic reprogramming augments potency of human pSTAT3-inhibited iTregs to suppress alloreactivity
2020-05-0711
OA